Background Patients with non-alcoholic fatty liver disease (NAFLD) and more advanced fibrosis tend to have more impairment in their health-related quality of life and other patient-reported outcomes (PROs). Aim To assess the association of PROs with select non-invasive tests (NITs) for fibrosis including FAST, Agile 3+ and Agile 4 scores Methods We enrolled patients with an established diagnosis of NAFLD who were seen in a tertiary care clinic into the NAFLD/NASH Registry. The FAST, Agile 3+ and Agile 4 scores were calculated using liver stiffness measurements by transient elastography and laboratory parameters. PROs were assessed using FACIT-F, CLDQ-NASH and WPAI instruments (total of 17 domain and summary scores). Results There were 1509 ...
Patient-reported outcomes (PROs) are used to measure patients' experience with their disease. Howeve...
Background: The accuracy of available non-invasive tools for staging severe fibrosis in patients wit...
Background & Aims: Fibrosis is the strongest predictor for long-term clinical outcomes among patient...
It remains unclear whether screening for advanced fibrosis in the community can identify the subgrou...
Background In nonalcoholic fatty liver disease (NAFLD), advanced fibrosis has been identified as ...
Objective: Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fat...
Background: Nonalcoholic Fatty Livery Disease (NAFLD) affects a large population in the US, with sig...
International audienceBecause only a minority of patients with nonalcoholic fatty liver disease (NAF...
Background The aim of this study was to evaluate the diagnostic accuracy of simple non-invasive tes...
Background: We evaluated the diagnostic accuracy of simple non-invasive tests(NITs) in NAFLD patient...
[Background] Patient-reported outcomes (PROs) are used to measure patients’ experience with their di...
Patient-reported outcomes (PROs) are important endpoints for clinical trials. The impact of investig...
BACKGROUND AND AIM: Progression to fibrosis in non-alcoholic fatty liver disease (NAFLD) is associat...
Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatt...
Background The presence of advanced liver fibrosis portends a poor prognosis in nonalcoholic fatty l...
Patient-reported outcomes (PROs) are used to measure patients' experience with their disease. Howeve...
Background: The accuracy of available non-invasive tools for staging severe fibrosis in patients wit...
Background & Aims: Fibrosis is the strongest predictor for long-term clinical outcomes among patient...
It remains unclear whether screening for advanced fibrosis in the community can identify the subgrou...
Background In nonalcoholic fatty liver disease (NAFLD), advanced fibrosis has been identified as ...
Objective: Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fat...
Background: Nonalcoholic Fatty Livery Disease (NAFLD) affects a large population in the US, with sig...
International audienceBecause only a minority of patients with nonalcoholic fatty liver disease (NAF...
Background The aim of this study was to evaluate the diagnostic accuracy of simple non-invasive tes...
Background: We evaluated the diagnostic accuracy of simple non-invasive tests(NITs) in NAFLD patient...
[Background] Patient-reported outcomes (PROs) are used to measure patients’ experience with their di...
Patient-reported outcomes (PROs) are important endpoints for clinical trials. The impact of investig...
BACKGROUND AND AIM: Progression to fibrosis in non-alcoholic fatty liver disease (NAFLD) is associat...
Objective Liver biopsy is still needed for fibrosis staging in many patients with non-alcoholic fatt...
Background The presence of advanced liver fibrosis portends a poor prognosis in nonalcoholic fatty l...
Patient-reported outcomes (PROs) are used to measure patients' experience with their disease. Howeve...
Background: The accuracy of available non-invasive tools for staging severe fibrosis in patients wit...
Background & Aims: Fibrosis is the strongest predictor for long-term clinical outcomes among patient...